Achilles Therapeutics
NASDAQ:ACHLAchilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
AECOM
NYSE:ACMAECOM, together with its subsidiaries, provides professional infrastructure consulting services worldwide. It operates in three segments: Americas, International, and AECOM Capital. The company offers planning, consulting, architectural and engineering design, construction and program management, and investment and development services to public and private clients. It is also involved in the investment and development of real estate projects. In addition, the company provides construction services, including building construction and energy, and infrastructure and industrial construction. It serves transportation, water, government, facilities, environmental, and energy sectors. The company was formerly known as AECOM Technology Corporation and changed its name to AECOM in January 2015. AECOM was incorporated in 1980 and is headquartered in Dallas, Texas.
CompuGroup Medical SE & Co. KGaA
OTCMKTS:CMPUYCompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. The company's Ambulatory Information Systems segment develop and sell practice management software for registered physicians, medical care centers, and physician networks; and offers supplementary internet and intranet solutions. Its Pharmacy Information Systems segment develop and sell administrative and billing related software applications, which includes procuring and shipping, managing and controlling inventory, planning, performing, and monitoring retail activities for pharmacies. Hospital Information Systems segment develop and sells of clinical and administrative solutions for inpatient sector; healthcare services to acute care hospitals, rehabilitation centers, welfare institutions, multi-location hospital networks, healthcare regions, regional care organizations, medical laboratories, and radiologists. The Consumer & Health Management Information Systems segment provides software interfaces for data exchange, portals for retrieving data from the German outpatient healthcare market, medical decision support tools, medication and treatment databases for healthcare service providers, solutions for the insurance industry, and digital healthcare applications, consumer portals, and mobile apps; and operates telematics infrastructure business, which offers secure links, as well as security solutions for service providers. The company was founded in 1987 and is headquartered in Koblenz, Germany.
Cue Biopharma
NASDAQ:CUECue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
MEDIROM Healthcare Technologies
NYSE:MRMMEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology. This segment operates relaxation salons under the Re.Ra.Ku and Ruam Ruam brands. The Digital Preventative Healthcare segment offers government-sponsored Specific Health Guidance program, utilizing Lav, an on-demand health monitoring smartphone application and MOTHER Bracelet for fitness applications; and preventative healthcare services utilizing nutritionists and health nurses. The Luxury Beauty segment manages and operates hair salons under the ZACC brand name. MEDIROM Healthcare Technologies Inc. also operates Re.Ra.Ku College that offers continuing training for franchise owners, home office staff, and salon staff covering topics, such as customer service, salon operations, and relaxation techniques. The company was formerly known as MEDIROM Inc. and changed its name to MEDIROM Healthcare Technologies Inc. in March 2020. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.